REMS Redesign: What FDA Heard From Stakeholders
This article was originally published in RPM Report
CDER Associate Director for Policy Jane Axelrad chaired the two day stakeholder meeting on REMS July 27-28, and delivered a remarkably cogent summary of about 15 hours presentations and discussion before adjourning the event. Here is here summary of the key takeaways from the meeting, excerpted from the official FDA transcript of the event.
You may also be interested in...
FDA has been perceived by drug developers as a regulator obsessed with drug safety. But recent cases show serious safety concerns aren’t holding back new products: efficacy has been the deciding factor for approval.
Biopharma companies are understandably upset by the Biden Administration’s decision to support a waiver of intellectual property protections on COVID vaccines. But over-reacting may only make matters worse.
Third-party cost-effectiveness reviewer ICER has a number of ideas for how US FDA could operate Accelerated Approval differently. But the group’s white paper raises a more fundamental questions: whether and how FDA should consider payer perspectives in regulatory decisions.